ERCC2 and urinary bladder cancer: NMIBC accounts for 80% of bladder cancer diagnoses and is found to carry mutations in the DNA helicase ERCC2, tumor suppressor TP53, and fibroblast growth factor receptor 3 (FGFR3) [16].